SEC Form 4 · accession 0001140361-18-010828
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Perry A Karsen
Director
Period of report
Feb 26, 2018
Accepted (ET)
Feb 28, 2018 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 26, 2018 | A | 70,500 | $0.00 | A | 80,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.29 | Feb 26, 2018 | A | 120,000 | A | — | Feb 26, 2028 | Common Stock | 120,000 | 120,000 | D |
Explanation of responses
- F1Grant of Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
- F2The option vests with respect to 1/6 of the shares subject thereto on each monthly anniversary of January 3, 2018, subject to the Reporting Person's continued service to the Issuer as Executive Chairman through each such vesting date.